# Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed

> **NCT00006006** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 38 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00006006
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2005-03
- **Final completion:** —
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2013-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006006, "Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00006006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*